HAEMONETICS CORP/MASS (HAE) Stock Analyst Ratings
USA • New York Stock Exchange • NYSE:HAE • US4050241003
66.66 USD
+0.7 (+1.06%)
At close: Jan 30, 2026
66.66 USD
0 (0%)
After Hours: 1/30/2026, 8:04:00 PM
ChartMill assigns a Buy % Consensus number of 79% to HAE. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 93.84. This target is 40.77% above the current price.
- HAE was analyzed by 15 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about HAE.
- In the previous month the buy percentage consensus was at a similar level.
- HAE was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-01-12 | Barrington Research | Maintains | Outperform -> Outperform |
| 2026-01-09 | BTIG | Reiterate | Buy -> Buy |
| 2025-12-17 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-12-15 | Needham | Downgrade | Buy -> Hold |
| 2025-12-15 | Baird | Maintains | Outperform -> Outperform |
| 2025-12-12 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-12-11 | Citigroup | Downgrade | Buy -> Neutral |
| 2025-11-21 | BTIG | Reiterate | Buy -> Buy |
| 2025-11-07 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-11-07 | Needham | Maintains | Buy -> Buy |
| 2025-11-06 | BTIG | Maintains | Buy -> Buy |
| 2025-10-21 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-10-07 | Citigroup | Maintains | Buy -> Buy |
| 2025-09-23 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-08-11 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2025-08-08 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-08-08 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-08-08 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2025-08-07 | Needham | Maintains | Buy -> Buy |
| 2025-07-11 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-07-09 | Citigroup | Upgrade | Neutral -> Buy |
| 2025-06-26 | Baird | Initiate | Outperform |
| 2025-05-20 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-05-09 | Raymond James | Reiterate | Strong Buy -> Strong Buy |
| 2025-05-08 | Needham | Maintains | Buy -> Buy |
| 2025-03-18 | Needham | Maintains | Buy -> Buy |
| 2025-02-07 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-02-07 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-02-07 | Needham | Maintains | Buy -> Buy |
| 2025-02-07 | Raymond James | Reiterate | Strong Buy -> Strong Buy |
HAEMONETICS CORP/MASS / HAE FAQ
What is the price target for HAE stock?
15 analysts have analysed HAE and the average price target is 93.84 USD. This implies a price increase of 40.77% is expected in the next year compared to the current price of 66.66.
How do analysts rate HAEMONETICS CORP/MASS (HAE)?
The consensus rating for HAEMONETICS CORP/MASS (HAE) is 78.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.